Table 2.
Factors associated with a normal LAVi.
| Variable | 6-month interval | 1-year interval | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI | p value | OR | 95% CI | p value | |
| Younger age | 1.18 | 1.06–1.31 | <0.01 | 1.22 | 1.06–1.42 | <0.01 |
| White race | 7.43 | 0.90–61.52 | 0.06 | 5.62 | 0.55–57.49 | 0.15 |
| ACE-I therapy | 3.67 | 0.54–25.17 | 0.19 | 6.73 | 0.66–68.34 | 0.11 |
| Decreased LVEDVi | 1.04 | 0.99–1.08 | 0.11 | |||
| Longer DT | 1.02 | 1.00–1.04 | 0.03 | |||
| E-to-A ratio | 8.84 | 1.05–74.29 | 0.05 | |||
The model suggested that the following risk factors are associated with an increased probability of having a normal LAVi with 6-month interval and 1-year interval between baseline and follow-up TTEs: younger age, white race, being on ACE-I therapy, smaller LVEDVi, longer DT, and higher E-to-A ratio. The model predicted an area under the curve of 0.95 (p < 0.0001) for the 6-month interval and 0.94 (p < 0.0001) for the 1-year interval. ACE-I, angiotensin-converting enzyme inhibitor; LVEDVi, indexed left ventricular end-diastolic volume; DT, deceleration time; E-to-A ratio, early-to-late mitral inflow velocity ratio; LAVi, indexed left atrial volume.